"This FDA approval marks a significant advancement for a specific subset of patients with advanced or metastatic breast cancer, offering a new treatment option precisely targeted at tumors that have developed resistance to endocrine therapy through ESR1 mutations."
The U.S. Food and Drug Administration (FDA) has granted full approval to the combination of imlunestrant (Inluriyo) and abemaciclib (Verzenio) for adult patients diagnosed with estrogen receptor-positive (ER-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer that harbors an ESR1 mutation. This pivotal approval is specifically for individuals whose disease has progressed after at least one line of prior endocrine therapy. Crucially, the imlunestrant and abemaciclib combination is only indicated for patients whose ESR1 mutation status is confirmed by an FDA-authorized testing method. Alongside the drug approval, the FDA also cleared the Guardant360 CDx assay as the companion diagnostic, a blood-based test essential for identifying eligible patients. Both imlunestrant and abemaciclib are developed by Eli Lilly and Company.
This targeted approval underscores a critical evolution in breast cancer treatment, moving beyond broad therapeutic strategies to embrace precision medicine. For patients, the practical implications are precise and defined. This is not a new initial treatment, but rather a vital option available at a crucial juncture: when standard hormone-blocking therapies have ceased to be effective, and a specific genetic alteration—an ESR1 mutation—is detected in the tumor. This mutation is a common mechanism of resistance in ER-positive, HER2-negative metastatic breast cancer, emerging in approximately half of patients during or after treatment with aromatase inhibitors, a cornerstone of endocrine therapy. The development of an ESR1 mutation signals a need for alternative therapeutic approaches that can overcome this acquired resistance.
The regulatory decision is underpinned by the robust findings of the EMBER-3 clinical trial, a randomized, open-label study that enrolled 874 adult participants. These patients had previously undergone treatment with an aromatase inhibitor, potentially in combination with a CDK4/6 inhibitor, and their disease had progressed. Participants in the trial were assigned to one of three treatment arms: imlunestrant as a single agent, an investigator’s choice of standard endocrine therapy, or the combination of imlunestrant with abemaciclib.
The data that primarily drove the FDA’s approval originated from an exploratory subgroup analysis focusing on 159 patients whose tumors demonstrably carried an ESR1 mutation. In this specific patient group, the combination of imlunestrant and abemaciclib demonstrated a median progression-free survival (PFS) of 11.1 months. This stands in stark contrast to the 5.5 months observed for patients treated with imlunestrant alone, representing a hazard ratio of 0.53, indicating a significant reduction in the risk of disease progression or death. Furthermore, the objective response rate (ORR) was substantially higher with the combination therapy, achieving 35% compared to 15% for imlunestrant monotherapy. These metrics highlight the clinical benefit of combining these two agents in patients with ESR1-mutated disease.
It is important to note certain limitations that temper the interpretation of these findings. Firstly, the overall survival (OS) data were considered immature at the time of the interim analysis. With deaths recorded in 35% of the ESR1-mutated group, the trial had not yet definitively demonstrated whether the combination therapy leads to a statistically significant improvement in overall survival. While progression-free survival measures the duration for which cancer is controlled, it is not a direct surrogate for longevity. Secondly, the FDA’s assessment revealed that imlunestrant, when used as a single agent, did not show an improvement in PFS over standard endocrine therapy in either the overall trial population or in the subgroup of patients lacking an ESR1 mutation. This observation strongly suggests that the benefit observed with the combination is largely confined to patients harboring the specific ESR1 mutation.
Dr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center, who served as the principal investigator for the EMBER-3 trial, articulated the strategic rationale behind this therapeutic approach. In Eli Lilly’s announcement of the approval, she emphasized that combining therapies targeting distinct drivers of tumor growth—the estrogen receptor pathway and the CDK4/6 pathway—represents "an important strategy to help address treatment resistance." This dual-targeting approach aims to overcome the mechanisms by which cancer cells adapt and evade single-agent therapies. It is noteworthy that Memorial Sloan Kettering has disclosed Dr. Jhaveri’s financial interests related to Eli Lilly, and the trial itself was sponsored by the company.
The critical role of a blood test in determining patient eligibility cannot be overstated. In the EMBER-3 trial, the identification of ESR1 mutation status was achieved through the analysis of circulating tumor DNA (ctDNA) extracted from a blood sample, a method known as liquid biopsy. This approach offers distinct advantages over traditional tissue biopsies. Liquid biopsies are generally less invasive, easier to obtain, and can be repeated more readily. This is particularly relevant given that ESR1 mutations are often acquired over time as the cancer evolves, rather than being present from the initial diagnosis. Therefore, the ability to re-test for mutations is crucial for identifying patients who may become eligible for this therapy as their disease progresses.
For patients currently undergoing endocrine therapy for advanced or metastatic breast cancer, a pertinent question to pose to their oncologist would be: "Has an ESR1 mutation test been performed on my tumor, and if so, when was it last conducted? Is a repeat test warranted given my current treatment status?" This inquiry is not about requesting a specific drug but about assessing eligibility for a targeted therapeutic option. The presence or absence of an ESR1 mutation, as confirmed by an authorized test, is the gatekeeper to accessing this new treatment combination.
The question of insurance coverage remains a significant hurdle for many patients. Both imlunestrant and abemaciclib are oral medications, typically covered under a health plan’s pharmacy benefit. However, drugs classified as specialty tier medications can involve substantial out-of-pocket costs through co-insurance or co-payments. Patients who encounter coverage denials can explore several avenues, including engaging their care team to initiate prior authorization requests, navigating the appeals process with their insurance provider, and investigating patient assistance programs offered by the drug manufacturer. The FDA’s approval of the drug combination does not, in itself, dictate pricing or guarantee insurance coverage.
The clinical benefit of the imlunestrant and abemaciclib combination comes with a notable tolerability profile, and patients must be aware of the potential side effects. In the EMBER-3 trial, diarrhea was a highly prevalent adverse event, reported in 86% of patients receiving the combination, with 9% experiencing severe (grade 3 or 4) diarrhea. Neutropenia, a reduction in neutrophil counts, also occurred in 86% of patients, with 21% experiencing grade 3 or 4 decreases. Other significant adverse events included interstitial lung disease or pneumonitis, observed in 2.9% of patients, and venous thromboembolic events, occurring in 4.8%.
Serious adverse reactions were reported in 21% of patients treated with the combination, and unfortunately, fatal adverse reactions occurred in 3.8% of cases. These fatal events were attributed to conditions such as pneumonia, myocardial infarction (heart attack), interstitial lung disease, and sepsis. While a significant proportion of adverse events were graded as mild to moderate, allowing patients to continue treatment, permanent discontinuation rates due to side effects were relatively low. Imlunestrant was discontinued permanently in 1% of patients, and abemaciclib in 3.4%.
Vigilant monitoring is an integral component of treatment with this combination. Patients will undergo regular assessments of their blood counts and liver function. These tests are typically conducted prior to initiating therapy, then every two weeks for the initial two months, monthly for the subsequent two months, and thereafter as clinically indicated. Both imlunestrant and abemaciclib carry significant warnings regarding embryo-fetal toxicity. Therefore, effective contraception is strongly advised for both male and female patients during treatment and for a specified period following its cessation.
The dosing regimen involves imlunestrant administered once daily on an empty stomach, while abemaciclib is taken twice daily. Treatment continues until disease progression or until the emergence of unacceptable side effects. Patients are advised to report any instances of loose stools promptly, as early intervention with antidiarrheal medication, increased fluid intake, and communication with their healthcare team is the standard approach to managing this common side effect.
This approval represents the second significant FDA clearance for imlunestrant within a relatively short timeframe. The drug previously received accelerated approval as a single agent in September 2025. This latest decision follows closely on the heels of another important regulatory event two weeks prior, when the FDA granted accelerated approval to camizestrant, another agent targeting the estrogen receptor, in combination with a CDK4/6 inhibitor. However, camizestrant’s accelerated approval was for use at an earlier stage of care: when a blood test detects an emerging ESR1 mutation during first-line therapy, even before imaging confirms disease progression. Looking ahead, results from EMBER-4, a large-scale trial investigating imlunestrant in the adjuvant setting (after surgery) for early breast cancer, involving over 8,000 patients, are anticipated in 2027. This ongoing research highlights the commitment to exploring the full potential of imlunestrant across different stages of breast cancer management.
Key Questions Answered
Who is this approval for?
This approval is for adult patients diagnosed with estrogen receptor-positive (ER-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer who have an ESR1 mutation and whose disease has progressed after at least one prior line of endocrine therapy.
How is eligibility determined?
Eligibility is determined through an FDA-authorized test that identifies the presence of an ESR1 mutation. The agency has approved the Guardant360 CDx assay, a blood-based liquid biopsy, as the companion diagnostic for this purpose.
What did the trial show?
The pivotal EMBER-3 trial, in a subgroup of 159 patients with ESR1 mutations, demonstrated a median progression-free survival of 11.1 months with the imlunestrant and abemaciclib combination, compared to 5.5 months with imlunestrant alone. The objective response rate was also significantly higher with the combination (35% vs. 15%).
Does it help people live longer?
The impact on overall survival has not yet been definitively established. Overall survival data were immature at the interim analysis of the EMBER-3 trial, meaning the trial has not yet provided conclusive evidence of a survival benefit.
What are the most common side effects?
The most frequently reported side effects in patients receiving the combination therapy include diarrhea and reduced neutrophil counts, each occurring in 86% of patients. Other common side effects can include reduced hemoglobin, nausea, fatigue, and various laboratory abnormalities.
Is this a first-line treatment?
No, this treatment combination is not indicated as a first-line therapy. It is approved for use in patients whose disease has progressed after at least one prior line of endocrine therapy.
What should patients ask their oncologist?
Patients should inquire whether ESR1 mutation testing has been performed, the date of the last test, and whether a repeat test is recommended, given that ESR1 mutations are often acquired during treatment and may not be present at initial diagnosis.
